Yes, I like concise and more questions like you laid out.

Picking up where I left off yesterday (and these have likely already been asked by others):

Cancer:
Provide a detailed explanation of TNBC delays (he said he would personally investigate)?
Updates on remaining sites opening?
Have they received IRB approval for these remaining sites?
Update and detailed explanation on open TNBC site patient recruiting and initial injection delay?
Do the multiple TNBC delays impact the previous management optimism of trial success?
Status of 8 cancer pre-clinical trials?
When can we expect results from these trials?
Colon IND (stated 1-2 weeks from filing over a month ago.....I haven't searched for the date stated yet)?

Financing / License Agreement / Partnerships:
Expected amount to raise from current TO?
Do they expect to extend or re-open the TO in the future?
Updates on commercialization pharma company agreement related to HIV and GVHD? Or does CYDY expect to commercialize Leronlimab?
Terms discussed in non-binding term sheet that was verbally accepted pending BOD approval from China investment?
Any progression in Samsung capital investment?
Updates on mid-tier pharma partnership?
Updates on Prognostic test license? Is this pending 510(k) FDA decision?
Do you still plan to win your $5 share price bet and if so how?

Other:
Any NASH updates?
GvHD updates?
When or do they expect to pursue MS indication?
Expected release date for Dr. Sacha HIV/Leronlimab research results?
Impacts of Dr. Rae (Business Development) so far?
How does he plan to increase share price (NP said he was up to the challenge a month or so ago in an interview)?
Details on up-list plan (RS....no based on previous comments; what we can expect to meet the requirements)?

I understand many of these won't make the cut, but was throwing out everything I could think of at the moment.